Pfizer Inc. (PFE)
| Market Cap | 141.46B |
| Revenue (ttm) | 62.79B |
| Net Income (ttm) | 9.83B |
| Shares Out | 5.69B |
| EPS (ttm) | 1.73 |
| PE Ratio | 14.41 |
| Forward PE | 8.20 |
| Dividend | $1.72 (6.91%) |
| Ex-Dividend Date | Nov 7, 2025 |
| Volume | 61,974,767 |
| Open | 25.35 |
| Previous Close | 25.45 |
| Day's Range | 24.72 - 25.50 |
| 52-Week Range | 20.92 - 27.69 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | 27.75 (+11.54%) |
| Earnings Date | Nov 4, 2025 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral pr... [Read more]
Financial Performance
In 2024, Pfizer's revenue was $63.63 billion, an increase of 6.84% compared to the previous year's $59.55 billion. Earnings were $8.03 billion, an increase of 279.00%.
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for PFE stock is "Buy." The 12-month stock price target is $27.75, which is an increase of 11.54% from the latest price.
News
October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs
This article highlights the October 2025 ReFa/Ro Dogs, focusing on high-yield, low-priced dividend stocks for contrarian income investors. Top projected net gainers include MFA, CIM, HAFN, IPG, and LY...
Pfizer: Is This Pharma Giant Finally A Bargain
Following Pfizer's victory over Novo Nordisk in the "war" for Metsera, its stock resumed its upward momentum. But before the deal was completed, it again beat Wall Street analysts' consensus EPS and r...
Pfizer in $41.5 million settlement with Texas over ADHD drug
Pfizer and supplier Tris Pharma reached a $41.5 million settlement with Texas to resolve claims over alleged quality control lapses in medicine to treat attention deficit hyperactivity disorder in chi...
Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript
Pfizer Inc. ( PFE) Jefferies London Healthcare Conference 2025 November 19, 2025 4:00 AM EST Company Participants David Denton - Executive VP & CFO Conference Call Participants Akash Tewari - Jefferi...
US-Saudi event to include CEOs from Chevron, Qualcomm, Pfizer, source says
The U.S.-Saudi Arabia investment forum to take place in Washington during the visit of Saudi Crown Prince Mohammed bin Salman this week is expected to include CEOs from Chevron, Qualcomm, Cisco, Gener...
3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List
The healthcare sector's renewed momentum offers fertile ground for investors wanting to outperform by picking the best stocks from the broader indexes. Goldman Sachs identified 29 healthcare stocks in...
Activist Starboard sells Pfizer stake after pushing for changes
Activist investor Starboard Value has liquidated its position in Pfizer , according to a regulatory filing on Friday, ending its push for changes aimed at boosting the drugmaker's share price.
Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman
Evan Seigerman, BMO Capital Markets head of health care research, joins 'Power Lunch' to discuss what's behind the recent move in health care stocks, the state of play with GLP-1s and much more.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Pfizer's ex-R&D chief Dolsten withdraws from Novo Nordisk board race
Mikael Dolsten, Pfizer's former research and development chief, has withdrawn his candidacy for Novo Nordisk's board, citing personal reasons, the Danish drugmaker said on Thursday.
Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up
Pfizer Inc said on Thursday said that it will sell 54.7% of its stake in German drugmaker BioNTech SE , over five years after both firms formed an alliance that yielded a vaccine to combat the deadly ...
Pfizer CEO: RFK Jr. "clearly" was not his HHS Secretary choice
Pfizer CEO Albert Bourla doesn't think RFK Jr.'s views on vaccines will have long-term risks: "Vaccines have saved the world and we will continue doing that." About Yahoo Finance: Yahoo Finance provid...
Pfizer CEO: AI will help with medicine's next big breakthrough
Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical gia...
Pfizer Completes Acquisition of Metsera
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating...
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
Pfizer (NYSE: PFE) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE (NASDAQ: BNTX).
Metsera shareholders vote for $10 billion acquisition by Pfizer
Metsera shareholders on Thursday approved Pfizer's takeover offer worth up to $10 billion, allowing the U.S. pharmaceutical giant re-entry into the lucrative obesity treatment market after a fierce bi...
BioNTech says collaboration with Pfizer remains unchanged
BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer is looking to sell its stake in the German biotech firm.
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice Pr...
Johnson Fistel Investigates Fairness of Proposed Sale of Metsera
SAN DIEGO, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached the...
Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript
Pfizer Inc. ( PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology November 10, 2025 8:30 AM EST Company Participants Francesca DeMartino - Chief Investor Relations O...
Pfizer to buy Metsera in deal worth up to $10 billion
Pfizer has clinched a $10 billion deal for obesity drug developer Metsera, capping a fierce biotech bidding war between the New York-based pharma giant and Danish rival Novo Nordisk. Metsera accepted ...
Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs
Pfizer CEO Albert Bourla joins Squawk on the Street to discuss the company's up to $10 billion acquisition of Metsera, the competitive landscape in obesity drugs, and Pfizer's strategy for clinical de...
Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.
Pfizer is buying its way back into the obesity-drug game after fighting off a rival bid from Novo Nordisk to buy Metsera, with more money and help from the Trump administration.